Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sphingosine-1-phosphate phosphatase 2 (SGPP2)
- Target
- SGPP2
- Molecular classification
- Enzyme, Lipid phosphatase, Transmembrane protein
01
Overview
Sphingosine-1-phosphate phosphatase 2 (SGPP2) is a transmembrane enzyme localized to the endoplasmic reticulum, where it specifically dephosphorylates sphingosine-1-phosphate (S1P)—a bioactive sphingolipid signaling molecule—regulating its intracellular concentration as part of sphingolipid and lipid mediator metabolism. SGPP2 plays a key role in diverting S1P away from signaling functions toward recycling and biosynthesis within the sphingolipid pathway. It is highly expressed in tissues such as pancreatic islets and the gastrointestinal tract, and its activity has been associated with the regulation of β-cell endoplasmic reticulum stress (implicating it in diabetes), and promotion of inflammatory processes and barrier disruption in colitis. SGPP2 is induced during inflammatory states and may be regulated by microRNA-31. As of now, there are no specific therapeutics known to target SGPP2 directly, but the enzyme is of interest for the development of new drugs for metabolic and inflammatory diseases.
- Other names
- SPPase2SPP2Spp2hSPP2FLJ39004Sphingosine-1-phosphatase 2sphingosine-1-phosphate phosphohydrolase 2sphingosine-1-phosphatase 2sphingosine-1-phosphate phosphotase 2
02
Mechanism of action
Therapeutic modulation is theoretical; would involve inhibition or enhancement of S1P dephosphorylation.
03
Biological functions
Sphingosine-1-phosphate (S1P) degradationSphingolipid metabolismAttenuation of intracellular S1P signalingRegulation of endoplasmic reticulum stress (especially in pancreatic β-cells)Regulation of cell proliferationPro-inflammatory signaling
04
Disease associations
Diabetes (β-cell dysfunction, ER stress in β-cells)Inflammation (promotes pro-inflammatory signaling, especially in colitis)Cancer (modulated by the tumor suppressor microRNA-31)Metabolic diseasePotential involvement in barrier dysfunction (e.g., ulcerative colitis)
05
Safety considerations
Possible disruption of sphingolipid homeostasisβ-cell dysfunction and ER stress, especially if inhibited (may contribute to diabetes development)Potential exacerbation of colitis or barrier dysfunction in gastrointestinal tract
Beyond the preview
Go deeper on Sphingosine-1-phosphate phosphatase 2 (SGPP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sphingosine-1-phosphate phosphatase 2 (SGPP2).